Vol 15, No 1 (2019)
Case report
Published online: 2019-04-16
Page views 687
Article views/downloads 533
Get Citation

Connect on Social Media

Connect on Social Media

Nivolumab in treatment of renal cell carcinoma during renal replacement therapy

Kamil Konopka1
Oncol Clin Pract 2019;15(1).

Abstract

The prolongation of overall survival of advanced RCC patients requires the use of modern therapies including tyrosine kinase inhibitors and immune checkpoint inhibitors. Although these drugs have different pharmacokinetics, preclinical studies rarely indicate significant renal clearance. To date there has been a lack of prospective studies evaluating their efficacy and safety in end-stage renal disease patients undergoing dialysis. This case study describes second-line treatment of RCC with nivolumab in a dialysed patient following bilateral nephrectomy.

Article available in PDF format

Purchase Subscription

References

  1. Markić D, Valencić M, Spanjol J, et al. Renal function outcomes after nephrectomy for kidney cancer in elderly patients. Coll Antropol. 2011; 35 Suppl 2: 121–124.
  2. Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
  3. Bajaj G, Wang X, Agrawal S, et al. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017; 6(1): 58–66.